Sonja M. Bragg

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease

Alette M. Wessels, Pierre N. Tariot, Jennifer A. Zimmer et al. · JAMA Neurology · 2019 · 191 citations · Full text

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Marc Ferrante, Geert D’Haens, Vipul Jairath et al. · The Lancet · 2024 · 76 citations

Moderately-to-severely Active Crohn, Immunology, Gastroenterology +5

Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study

Messoud Ashina, Uwe Reuter, Timothy R. Smith et al. · Cephalalgia · 2021 · 68 citations · Full text

Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine

Cristina Tassorelli, Sonja M. Bragg, JH Krege et al. · The Journal of Headache and Pain · 2021 · 26 citations · Full text

OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study

Vipul Jairath, Bruce E. Sands, Peter Bossuyt et al. · Journal of Crohn s and Colitis · 2024 · 26 citations · Full text

Chronic Inflammatory Diseases, Immunology, Gastroenterology +16